Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Results suggest SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a…
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Patients who achieved remission within three months sustained remission to six months.
Small Pharma announces further positive data from SPL026 Phase IIa trial in Major Depressive Disorder strengthening topline efficacy results
Statistically significant improvement in anxiety symptoms offers potential in indications beyond depression.
The state of depression treatments today – Dr David Erritzoe
Dr. David Erritzoe shares his thoughts from a psychiatrist perspective.
What is deuteration? Small Pharma’s Phase I Trial with SPL028 – Dr Carol Routledge
Dr. Carol Routledge discusses our SPL028 Phase I healthy volunteer trial.
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
The Phase I study will compare IV and IM routes of SPL028 administration.
Small Pharma reports positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder
Primary endpoint met. SPL026 demonstrates rapid and durable response.
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
Study will compare the profile of intramuscular versus intravenous SPL026 administration.
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
Last patient last visit complete in SPL026 Phase IIa clinical trial, plus new European patent…
First patient dosed in Small Pharma’s Drug Interaction study
Open-label study will assess the interaction between SSRI antidepressants and SPL026.